 |
Previous Article | Next Article 
The Journal of Neuroscience, May 1, 2000, 20(9):3095-3103
Evidence That Gz-Proteins Couple to Hypothalamic
5-HT1A Receptors In Vivo
F.
Serres,
Q.
Li,
F.
Garcia,
D. K.
Raap,
G.
Battaglia,
N. A.
Muma, and
L. D.
Van de Kar
Department of Pharmacology, Stritch School of Medicine, Loyola
University of Chicago, Maywood, Illinois 60153
 |
ABSTRACT |
Using in situ hybridization and immunoblot analysis,
the present studies identified Gz mRNA and
Gz-protein in the hypothalamic paraventricular nucleus. The
role of Gz-proteins in hypothalamic 5-HT1A
receptor signaling was examined in vivo. Activation of 5-HT1A receptors increases the secretion of oxytocin and
ACTH, but not prolactin. Intracerebroventricular infusion (3-4 d) of Gz antisense oligodeoxynucleotides, with different
sequences and different phosphorothioate modification patterns, reduced
the levels of Gz-protein in the hypothalamic
paraventricular nucleus, whereas missense oligodeoxynucleotides had no
effect. Neither antisense nor missense oligodeoxynucleotide treatment
altered basal plasma levels of ACTH, oxytocin, or prolactin, when
compared with untreated controls. An antisense-induced decrease in
hypothalamic Gz-protein levels was paralleled by a
significant decrease in the oxytocin and ACTH responses to the
5-HT1A agonist 8-hydroxy-dipropylamino-tetralin (8-OH-DPAT). In contrast, the prolactin response to 8-OH-DPAT (which cannot be blocked by 5-HT1A antagonists) was not
inhibited by Gz antisense oligodeoxynucleotides.
Gz-proteins are the only members of the
Gi/Go-protein family that are not
inactivated by pertussis toxin. In a control experiment, pertussis
toxin treatment (1µg/5 µl, i.c.v.; 48 hr before the 8-OH-DPAT
challenge) did not inhibit the ACTH response, potentiated the oxytocin
response, and eliminated the prolactin response to 8-OH-DPAT. Thus,
pertussis toxin-sensitive Gi/Go-proteins
do not mediate the 5-HT1A receptor-mediated increase in
ACTH and oxytocin secretion. Combined, these studies provide the first
in vivo evidence for a key role of
Gz-proteins in coupling hypothalamic 5-HT1A
receptors to effector mechanisms.
Key words:
serotonin; receptor; oxytocin; ACTH; prolactin; G-protein; signaling; signal transduction; hormones; neuroendocrine; hypothalamus; paraventricular
 |
INTRODUCTION |
Heterotrimeric
guanine-nucleotide-binding proteins (G-proteins) transduce
extracellular signals to intracellular messengers. Gz-protein is a member of the
Gi-protein family with a 41-67% of sequence
homology with Gi- and
Go-proteins (Fong et al., 1988 ; Matsuoka et al.,
1988 ). Unlike the other members of the Gi-protein family, Gz-protein lacks the cysteine residue in
the C terminus that serves as the substrate for pertussis
toxin-catalyzed ADP ribosylation (Casey et al., 1990 ). This lack of a
cysteine residue makes Gz-protein the only member
of the Gi/o-protein family known to be
insensitive to pertussis toxin and provides a valuable means to
identify the involvement of Gz-protein in
physiological responses. In vitro studies indicate that
5-HT1A receptors are coupled to members of the
Gi/Go-protein family,
including the pertussis toxin-sensitive Gi1-,
Gi2-, Gi3-, and
Go-proteins, and the pertussis toxin-insensitive Gz-protein (Butkerait et al., 1995 ; Albert et
al., 1996 ; Barr et al., 1997 ). Gz-protein is
involved in 5-HT1A receptor-mediated inhibition
of adenylyl cyclase in Sf9 cells (Butkerait et al., 1995 ; Barr et al.,
1997 ). In spite of extensive in vitro studies, little is
known about the nature of the receptors that couple to
Gz-proteins in vivo. It is still
unknown which G-proteins couple hypothalamic
5-HT1A receptors to the secretion of ACTH and
oxytocin. The present studies investigated the possible coupling of
Gz-proteins to 5-HT1A
receptor signaling in the hypothalamus in vivo.
Neuroendocrine challenges provide a noninvasive approach to study the
responsivity of hypothalamic postsynaptic 5-HT1A
receptors in vivo (Cowen, 1998 ). Serotonergic nerve
terminals make synaptic connections with oxytocin and corticotropin
releasing hormone (CRH)-containing neurons in the paraventricular
nucleus of the hypothalamus (Liposits et al., 1987 ; Saphier, 1991 ;
Kawano et al., 1992 ). Neurons in the paraventricular nucleus express
5-HT1A receptors (Li et al., 1997a ). Activation
of 5-HT1A receptors by a
5-HT1A agonist, such as
8-hydroxy-dipropylamino-tetralin (8-OH-DPAT), induces an
increase in oxytocin and CRH secretion (Calogero et al., 1989 ; Bagdy,
1996 ). CRH subsequently stimulates the secretion of ACTH from the
pituitary gland into the circulation. The ACTH and oxytocin responses
to 8-OH-DPAT can be inhibited by the selective 5-HT1A antagonist WAY-100,635 (Vicentic et al.,
1998 ). In contrast with ACTH and oxytocin, the prolactin response to
8-OH-DPAT is not blocked by 5-HT1A antagonists,
indicating that prolactin secretion induced by 8-OH-DPAT is mediated by
other receptors (Aulakh et al., 1988 ; Vicentic et al., 1998 ).
Therefore, in the present studies, plasma ACTH and oxytocin levels were
used as peripheral indices of hypothalamic 5-HT1A
receptor function. As a negative control, ACTH and oxytocin responses
to 8-OH-DPAT were compared with that of prolactin.
Initially, the expression of Gz mRNA and
Gz-protein in the hypothalamic paraventricular
nucleus was examined using in situ hybridization and
immunoblot analysis, respectively. Subsequently, two approaches were
used to examine the functional role of
Gz-proteins in 5-HT1A
receptor-mediated hormone secretion: (1) an antisense strategy to
specifically reduce the level of Gz-protein in
the hypothalamic paraventricular nucleus and (2)
intracerebroventricular pretreatment with pertussis toxin. In both
experiments, rats were challenged with the 5-HT1A
agonist 8-OH-DPAT to test whether the physiological responses triggered
by activation of hypothalamic 5-HT1A receptors
are mediated by Gz-protein.
 |
MATERIALS AND METHODS |
Animals
Male Sprague Dawley rats (225-275 gm) were purchased from
Harlan (Indianapolis, IN). The rats were housed two per cage in lighting- (12 hr light/dark: lights on at 7:00 A.M.), humidity-, and
temperature-controlled conditions. Food and water were available ad libitum. All procedures were conducted in accordance with
the National Institutes of Health Guide for the Care and Use of
Laboratory Animals as approved by the Loyola University Institutional
Animal Care and Use Committee.
 |
Drugs |
HPLC-purified oligodeoxynucleotides were purchased from Genosys
Biotechnologies (The Woodlands, TX). Pertussis toxin was purchased from
Sigma (St. Louis, MO). (±)8-OH-DPAT HBr was purchased from Research
Biochemicals (Natick, MA). All drugs were dissolved in saline.
Pertussis toxin was intracerebroventricularly injected in a
volume of 5 µl.
Two experiments with antisense oligodeoxynucleotides were designed
because the first experiment revealed a nonspecific toxicity of the
phosphorothioate Gz antisense
oligodeoxynucleotides. In the first experiment, the sequence of
G z antisense corresponding to nucleotide
sequence 308-323 was 5'-TCGTAGGCACGGTCA, and the sequence for missense
was 5'-CTGCAGGTATGGCTA. These 15 mer oligodeoxynucleotides were
phosphorothioate-modified at all positions to delay their degradation
and were infused using Alzet osmotic minipumps for 3 consecutive days.
Because the first batch of antisense oligodeoxynucleotide produced a
reduction in Gz-, Gi1- and
Gi2-protein levels in the paraventricular
nucleus, in the second experiment, the (33 base) G z antisense
oligodeoxynucleotide was modified to correspond to nucleotide sequence
330-363. The sequence was 5'-CGTGATCTCACCCTTGCTCTCTGCCGGGCCAGT-3', and the oligodeoxynucleotide was only phosphorothioate-modified at the
two bases of each end (5'-CG and GT-3') (Sanchez-Blazquez et al.,
1995 ). The sequence of the missense oligodeoxynucleotide was
5'-CCCTTATTTACTTTCGCC-3', and it was phosphorothioate modified at
positions 5'-CC and GC-3' (Sanchez-Blazquez et al., 1995 ). In all
experiments, saline or 8-OH-DPAT were injected subcutaneously in a
volume of 1 ml/kg.
 |
Surgery |
After several days of adaptation to their home cage,
intracerebroventricular cannulae were implanted in the rats by
stereotaxic surgery. For the Gz antisense
experiment, rats were anesthetized with xylazine (6.7 mg/kg)-ketamine
(100 mg/kg). An L-shaped cannula (Plastics One, Roanoke, VA) was
implanted into the third cerebral ventricle at stereotaxic coordinates
1.5 mm caudal and 0.0 mm lateral with respect to bregma and 9.5 mm
ventral from the skull surface. Positioning the tip of the cannula in
the third ventricle instead of inside the paraventricular nucleus was
intended to spare the neurons from mechanical damage. Damage to
hypothalamic neurons would produce a reduced hormone response to the
5-HT1A agonist, which could be misinterpreted as
a reduction in receptor coupling. A stainless steel obturator ensured
that the cannula would stay patent. The cannulae were kept in place by
dental cement attached to miniscrews embedded in the skull. The rats
received a subcutaneous injection of saline (1 ml) and ampicillin (50 mg/kg, s.c.) after surgery to prevent dehydration and infection,
respectively, and were returned to their home cage. The position of the
cannula tracks was carefully verified in each animal when the brains
were subsequently sectioned in a cryostat. The procedures for the
pertussis toxin experiment were similar except that a cannula was
implanted in the lateral cerebral ventricle (0.5 mm caudal, 1.4 mm
lateral from bregma and 4.5 mm ventral to the surface of the skull).
Experimental protocols
Gz antisense experiment
At least 10 d after cannula implantation, rats were
randomly assigned to groups that received either missense or antisense oligodeoxynucleotides. Untreated animals were used as controls to
verify for nonselective toxicity of the nucleotides.
First antisense experiment. Osmotic mini-pumps (Alzet
model 1003; Alza, Palo Alto, CA) were used for chronic microinfusions of the 15 mer phosphorothioate modified G z
antisense oligodeoxynucleotides (0.426 µg/µl; 0.093 nmol/µl), or
missense oligodeoxynucleotides (0.426 µg/µl; 0.095 nmol/µl) into
the third ventricle, allowing a sustained delivery at a rate of 1 µl/hr for 3 d. The osmotic minipumps were implanted
subcutaneously between the scapulae under halothane anesthesia and
connected to the cannulae with silicone rubber tubing (Plastics One).
The incisions were closed with sterile clips, and the rats were
returned to their home cage. On the fourth day, the rats received an
injection of either saline (1 ml/kg, s.c.) or 8-OH-DPAT (50 µg/kg,
s.c.) and were decapitated 15 min after the injection. Trunk blood was
collected in tubes containing 0.5 ml of a 0.3 M EDTA, pH
7.4, solution and centrifuged at 4°C. Plasma aliquots were stored at
70°C until they were used for hormone radioimmunoassays. The brains
were removed and rapidly frozen with dry ice, then stored at 70°C
for the microdissection of the hypothalamic paraventricular nucleus.
Second antisense experiment. Osmotic minipumps (Alzet model
2001; Alza) were used for chronic microinfusions of
G z antisense oligodeoxynucleotides or missense
oligodeoxynucleotides (0.2083 nmol/µl) into the third ventricle,
allowing a sustained delivery at a rate of 1 µl/hr for 4 d. The
dose was increased approximately twofold (compared with the first
experiment) to compensate for the higher vulnerability to degradation
of the nucleotides, which are only modified at the two bases on each
end of the molecule. The osmotic minipumps were implanted between the
scapulae under halothane anesthesia and connected to the cannulae with
silicone rubber tubing (Plastics One). The incisions were closed with
sterile clips, and the rats were returned to their home cage. On the
fifth day, the rats received an injection of either saline (1 ml/kg, s.c.) or 8-OH-DPAT (50 µg/kg, s.c.) and were decapitated 15 min after
the injection. Trunk blood was collected as described for experiment 1, and plasma aliquots were stored at 70°C until they were used for
hormone radioimmunoassays. The brains were removed and rapidly frozen
with dry ice, then stored at 70°C for the microdissection of the
hypothalamic paraventricular nucleus.
Pertussis toxin experiment
At least 10 d after surgical implantation of the cannulae,
the rats received 5 µl (intracerebroventricularly) of either saline or pertussis toxin (0.2 µg/µl; total of 1 µg/5 µl) through the cannulae and were returned to their home cage. Forty-eight hours later,
the rats were challenged with saline or 8-OH-DPAT (50 µg/kg, s.c.)
and were decapitated 15 min after the injection. Trunk blood was
collected in tubes containing 0.5 ml of a 0.3 M EDTA, pH
7.4, solution and centrifuged at 4°C. Plasma aliquots were stored at 70°C until they were used for hormone radioimmunoassays.
Molecular and biochemical assays
In situ hybridization
Gz mRNA was examined in cells in the
hypothalamic paraventricular nucleus using in situ
hybridization. The brain was removed and blocked, frozen, and stored at
70°C. Ten-micrometer-thick sections were cut on a cryostat and then
fixed in 4% paraformaldehyde at 4°C. Using previously described
methods (Muma et al., 1990 ), tissue sections (10 µm) were rinsed and
then acetylated in 0.25% acetic anhydride in 0.1 M triethanolamine hydrochloride. After dehydration, tissue sections were hybridized with
35S-labeled cDNA probes overnight at
37°C. The cDNA probe for Gz was a generous gift
from Dr. Yoshio Kaziro (Tokyo Institute of Technology, Tokyo, Japan).
The hybridization buffer consisted of 50% formamide, 4× SSPE,
Denhardt's solution, 200 µg/ml ssDNA and tRNA, and 20 mM dithiothreitol. Probes were labeled using a
Nick translation kit (Boehringer Mannheim, Mannheim, Germany). Slides
were washed in 1× SSC (150 mM sodium chloride
and 15 mM sodium citrate) at 50°C, dried, and
dipped in NTB2 (Eastman Kodak, Rochester, NY) nuclear emulsion. After
incubation for 3-4 weeks, silver grains were developed, fixed, and
sections were stained with cresyl violet.
Immunoblot analysis
Tissue dissection. G z-,
G i1-, and G i2-protein
levels were measured in micropunches of the paraventricular nucleus of
the hypothalamus. Rat brains were placed in a cryostat at 10°C, and coronal sections were cut to obtain a 700 µm section containing the
paraventricular nucleus. Using the diagram in Figure
1, the paraventricular nucleus was
microdissected from this section with the aid of a
stereomicroscope.

View larger version (18K):
[in this window]
[in a new window]
|
Figure 1.
Diagrammatic representation of the microdissection
of the hypothalamic paraventricular nucleus from coronal sections (700 µm). The landmarks used to identify the coronal section are those
seen at 1.8 mm caudal to bregma according to Paxinos and Watson (1986) .
F, Fornix; PVN, paraventricular nucleus
of the hypothalamus.
|
|
Protein fractionation. All procedures were conducted at
4°C unless otherwise indicated. Briefly, the tissues were homogenized in 0.5 ml of a 50 mM Tris buffer, pH 7.4, containing 150 mM NaCl, 10% sucrose, and 0.5 mM
phenylmethanesulfonyl fluoride (PMSF). After centrifugation at
20,000 × g for 60 min, the pellets (containing the
membrane-bound proteins) were solubilized in a 20 mM Tris buffer, pH 8, containing 1 mM EDTA, 100 mM NaCl, 0.1%
sodium cholate, and 1 mM dithiothreitol in a
ratio of 3 µl of buffer per milligram of tissue. The resuspended
homogenates were incubated and shaken for 1 hr, followed by
centrifugation at 100,000 × g for 60 min. The
supernatant (containing the membrane-bound G-proteins) was collected
and stored for the determination of membrane-bound G-protein levels.
Protein concentrations were measured according to Lowry et al. (1951)
using bovine serum albumin as a standard.
Quantification of G-proteins. The solubilized proteins (1.6 µg/lane) were resolved by SDS-PAGE, using 0.75-mm-thick
Tris-glycine denaturing reducing gels, containing 0.1% SDS,
12.5% acrylamide/bisacrylamide (30:0.2), 4.6 M urea, and
375 mM Tris, pH 8.7 (Mullaney and Miligan, 1990 ). The
proteins were then electrophoretically transferred for 2 hr to
nitrocellulose membranes, which were then allowed to dry. The membranes
were incubated at room temperature in a solution containing 5% nonfat
dry milk, 0.05% NP-40, 50 mM Tris, and 150 mM
NaCl, pH 7.4, for 1 hr and were then washed. The membranes were
incubated with polyclonal antisera for Gz (I-20;
Santa Cruz Biotechnology, Santa Cruz, CA; 1:6000 dilution) or
Gi1/2 (AS/7; DuPont NEN, Boston, MA; 1:2500
dilution), at 4°C overnight. Membranes were then incubated at room
temperature with a secondary antibody (goat anti-rabbit serum; Organon
Teknika Cappel, Durham, NC; 1:5000 dilution) for 60 min. After four
washes with 0.05% NP-40 in 50 mM Tris and 150 mM NaCl, the membranes were incubated with rabbit peroxidase-antiperoxidase (Organon Teknika Cappel; 1:10,000) for 1 hr. The membranes were incubated with the ECL chemiluminescence substrate solution (Amersham, Arlington Heights, IL) for 1 min and then
exposed to Kodak x-ray film for 10-60 sec.
G-protein data analysis. Films were analyzed
densitometrically using NIH Image (version 1.57) for Macintosh
computers. The gray scale density readings were calibrated using a
transmission step wedge standard. The integrated optical density (IOD)
of each band was calculated as the sum of optical densities of all the pixels within the area of the band outlined. An area adjacent to the
G-protein bands was used to calculate the background optical density of
the film. The IOD for the film background was subtracted from the IOD
for each band. The resulting IOD for each G-protein band was then
divided by the amount of protein loaded on the corresponding lane.
Three samples from each treatment group and three randomly selected
control samples were loaded on each gel. Each sample was measured on
three independent gels. To control for intergel variability, a mean IOD
per microgram of protein was obtained from the three controls on
each gel. To determine the relative amounts of the G-proteins per
sample, the IOD per microgram of protein value for each sample was
divided by the mean IOD per microgram of protein value obtained from
control samples on the same gel. Data for each rat were expressed as
"% of control." Because tissue samples were measured on three
independent gels, the mean % of control obtained from the three gels
represented the data for each rat.
Radioimmunoassays
Plasma ACTH and prolactin were measured by radioimmunoassays as
detailed previously (Li et al., 1993 ). ACTH antiserum was purchased
from IgG Corporation (Nashville, TN). ACTH (1-39) standards were
obtained from Calbiochem (San Diego, CA). Bovine serum albumin and
aprotinin were purchased from Sigma. Normal rabbit serum and goat
anti-rabbit- -globulin were purchased from Calbiochem.
125I-ACTH was obtained from DiaSorin
(Stillwater, MN). Kits for prolactin radioimmunoassay were provided by
the National Institute of Arthritis, Diabetes, Digestive, and Kidney
Disorders (NIADDK). Plasma oxytocin was assayed as detailed in our
previous paper (Li et al., 1997b ). For oxytocin extraction from plasma,
acetone (Spectranalyzed A-19) and petroleum ether were obtained from
Fisher Scientific (Pittsburgh, PA). The oxytocin antiserum was a
generous donation by Dr. Lanny Keil (Ames Research Center, Sunnyvale
CA). 125I-oxytocin was purchased from
DuPont NEN at a specific activity of 135 Ci/mmol.
Statistics
The data are presented as group means with the SEM
values. The G-protein data were analyzed by a one-way ANOVA, and
group means were compared by Newman-Keuls' multiple range test (Steel and Torrie, 1960 ). The hormone data were analyzed by a two-way ANOVA,
and group means were compared by Newman-Keuls' multiple range test
(Steel and Torrie, 1960 ). GB-STAT software (Dynamic Microsystems,
Silver Spring, MD) was used for all the statistical analyses.
 |
RESULTS |
In situ hybridization
Figure 2 shows a coronal section
through the hypothalamus at a high magnification of 330×
(A) and a dark-field picture of a lower magnification
(B). High grain density was observed in cells of the
hypothalamic paraventricular nucleus, indicating the expression of mRNA
encoding G z.

View larger version (72K):
[in this window]
[in a new window]
|
Figure 2.
In situ hybridization of
Gz mRNA in the hypothalamic paraventricular nucleus.
A, High magnification (330×) of cells in the
paraventricular nucleus expressing Gz mRNA; B,
dark-field low level magnification of the hypothalamus.
|
|
Gz antisense experiments
Figure 3A displays
immunoblots of different amounts of homogenate obtained from
microdissected tissue containing the hypothalamic paraventricular
nucleus. Loading increasing amounts of protein resulted in increased
IOD of the bands on the immunoblots. The levels of
Gz-protein in the paraventricular nucleus are
sufficiently high to allow detection when 1.6 µg of total protein was
loaded on the gel.

View larger version (42K):
[in this window]
[in a new window]
|
Figure 3.
A, Immunoblots showing the
expression of Gz-proteins in the hypothalamic
paraventricular nucleus. The numbers below indicate the
amount of protein loaded on each lane of the gel. B,
Immunoblots demonstrating the changes in Gz-proteins in the
hypothalamic paraventricular nucleus after treatment with missense or
Gz antisense oligodeoxynucleotides.
|
|
Levels of Gz-protein
Figure 3B illustrates immunoblots of
Gz-proteins obtained from control rats and from
rats treated with missense or antisense oligodeoxynucleotides. Missense
treatment did not result in a substantial reduction in the
Gz-protein band, whereas treatment with antisense
oligodeoxynucleotides substantially decreased the integrated optical
density of the Gz band (Fig. 3B). In
the first experiment, treatment with 15 mer antisense
oligodeoxynucleotides that were phosphorothioate-modified at all
positions produced a decrease (by 41%) in
Gz-protein levels, compared with untreated rats
(F(2,23) = 6.076; p < 0.01), whereas treatment with missense oligodeoxynucleotides did not
significantly reduce the levels of Gz-proteins in
the paraventricular nucleus (Table 1).
However, this antisense treatment also reduced the levels of
Gi1 and Gi2-proteins (40-50%; Table 1), suggesting nonspecific changes.
View this table:
[in this window]
[in a new window]
|
Table 1.
Effects of completely phosphorothioated, 15 mer missense
and Gz antisense oligodeoxynucleotides on the levels of
Gz, Gi1, and Gi2 proteins in
hypothalamic paraventricular nucleus "punches"
|
|
In a second experiment, we tested longer oligodeoxynucleotides that
were only phosphorothioate-modified at the two bases on each end.
Figure 4 shows the mean percent reduction
in Gz-, Gi1-, and
Gi2-protein levels in the paraventricular
nucleus. Antisense treatment produced a decrease of 38.5% in
Gz-protein levels, compared with missense, and
41.2% compared with untreated rats
(F(2,19) = 4.1423; p < 0.05). Treatment with missense oligodeoxynucleotides did not reduce
the levels of Gz-proteins in the paraventricular nucleus (Fig. 4). The levels of Gi1 and
Gi2-proteins were not reduced by either antisense
or missense treatments (Fig. 4).

View larger version (38K):
[in this window]
[in a new window]
|
Figure 4.
Effect of Gz antisense
oligodeoxynucleotides on the levels of Gz-,
Gi1-, and Gi2-proteins in the hypothalamic
paraventricular nucleus. The data represent the mean ± SEM of
seven or eight rats per group. *Significant difference from the
missense and uninjected group, p < 0.05 (one-way
ANOVA and Newman-Keuls' test).
|
|
Hormone responses to 8-OH-DPAT
In both experiments, basal levels of oxytocin, ACTH, and prolactin
were not significantly different among untreated, missense-treated, and
antisense-treated rats.
In the first antisense experiment, administration of 8-OH-DPAT (50 µg/kg, s.c.) increased plasma oxytocin by 888% (Fig.
5A), ACTH by 693% (Fig.
5B), and prolactin by 118% (Fig. 5C) in
untreated rats. Treatment with 15 mer phosphorothioate-modified
Gz antisense oligodeoxynucleotides produced a
significant inhibition of the oxytocin response to 8-OH-DPAT, by 43%
compared with untreated controls, and by 35% compared with
missense-treated rats (Fig. 5A). The two-way ANOVA indicated
a significant main effect of treatment
(F(2,46) = 3.38; p < 0.05), a significant main effect of 8-OH-DPAT
(F(1,46) = 101.8; p < 0.001), and a significant interaction between 8-OH-DPAT and
oligodeoxynucleotide treatment
(F(2,46) = 3.796; p < 0.05). Post hoc Newman-Keuls' test indicated that the
oxytocin response to 8-OH-DPAT is significantly decreased in
antisense-treated rats compared to missense-treated rats
(p < 0.05) and untreated rats
(p < 0.01).

View larger version (31K):
[in this window]
[in a new window]
|
Figure 5.
Effect of completely phosphorothioate-modified 15 mer Gz antisense oligodeoxynucleotides on the oxytocin
(A), ACTH (B), and
prolactin (C) responses to 8-OH-DPAT (50 µg/kg,
s.c.). The data represent the mean ± SEM of seven or eight rats
per group. *Significant effect of Gz antisense
oligodeoxynucleotides, p < 0.01 (Newman-Keuls'
test).
|
|
Treatment with Gz antisense oligodeoxynucleotides
also significantly decreased the ACTH response to 8-OH-DPAT, by 51%
compared to the missense group and by 42% compared with untreated rats (Fig. 5B). The two-way ANOVA indicated no main effect of
antisense treatment (F(2,45) = 2.30;
p > 0.10), a significant main effect of 8-OH-DPAT
(F(1,45) = 48.1; p < 0.0001), and a significant interaction between oligodeoxynucleotide
treatment and 8-OH-DPAT (F(2,45) = 3.27; p < 0.05). A post hoc Newman-Keuls'
test indicated that the response to 8-OH-DPAT is significantly
decreased in Gz antisense-treated rats compared
with missense-treated rats (p < 0.05).
8-OH-DPAT significantly increased the plasma levels of prolactin in
untreated rats, missense-, and Gz
antisense-treated rats (Fig. 5C). The two-way ANOVA
indicated no significant main effect of the treatment
(F(2,46) = 0.29; p > 0.10), a main effect of 8-OH-DPAT
(F(1,46) = 30.929; p < 0.01), and no significant interaction between oligonucleotide
treatment and 8-OH-DPAT (F(2,46) = 0.0783; p > 0.10).
In the second antisense experiment, administration of 8-OH-DPAT (50 µg/kg, s.c.), increased plasma oxytocin by 1274% (Fig. 6A), ACTH by 860%
(Fig. 6B), and prolactin by 300% (Fig.
6C) in untreated rats. The oxytocin response to 8-OH-DPAT
was not significantly different in missense-treated rats when compared
to untreated rats. However, treatment with the partly
phosphorothioate-modified 33 mer Gz antisense
oligodeoxynucleotides reduced the oxytocin response to 8-OH-DPAT by
39% compared with untreated controls and by 25% compared with
missense-treated rats (Fig. 6A). The two-way ANOVA
indicated a significant main effect of 8-OH-DPAT (F(1,31) = 170.5; p < 0.001), a significant main effect of treatment (F(2,31) = 3.73; p < 0.05), and a significant interaction between 8-OH-DPAT and
oligodeoxynucleotide treatment
(F(2,31) = 4.09; p < 0.05). A post hoc Newman-Keuls' test indicated that the
oxytocin response to 8-OH-DPAT is significantly decreased in
antisense-treated rats compared to control rats
(p < 0.05).

View larger version (25K):
[in this window]
[in a new window]
|
Figure 6.
Effect of partially phosphorothioate-modified 33 mer Gz antisense oligodeoxynucleotides on the oxytocin
(A), ACTH (B), and
prolactin (C) responses to 8-OH-DPAT (50 µg/kg,
s.c.). The data represent the mean ± SEM of seven or eight rats
per group. *Significant effect of Gz antisense
oligodeoxynucleotides, p < 0.01 (Newman-Keuls'
test).
|
|
Treatment with Gz antisense oligodeoxynucleotides
also significantly decreased the ACTH response to 8-OH-DPAT, by 35%
compared to the missense group, and by 49% compared with untreated
rats (Fig. 6B). The two-way ANOVA indicated a
significant main effect of antisense treatment
(F(2,31) = 5.23; p < 0.05), a significant main effect of 8-OH-DPAT
(F(1,31) = 109.8; p < 0.0001), and a significant interaction between oligodeoxynucleotide
treatment and 8-OH-DPAT (F(2,31) = 5.45; p < 0.01). A post hoc Newman-Keuls' test indicated that the response to 8-OH-DPAT is significantly decreased in Gz antisense-treated rats compared
with missense-treated (p < 0.05) and control
rats (p < 0.01).
8-OH-DPAT significantly increased the plasma levels of prolactin in
untreated, missense-treated, and Gz
antisense-treated rats (Fig. 6C). The two-way ANOVA
indicated no significant main effect of the treatment
(F(2,30) = 2.18; p > 0.1), a significant main effect of 8-OH-DPAT
(F(1,31) = 41.51; p < 0.01), and no significant interaction between oligodeoxynucleotide
treatment and 8-OH-DPAT (F(2,31) = 2.09; p > 0.1).
Pertussis toxin experiment
Treatment with pertussis toxin also did not alter the basal plasma
levels of oxytocin (Fig. 7A).
Injection of 8-OH-DPAT to vehicle-pretreated rats increased plasma
levels of oxytocin (by 963%; Fig. 7A). Pretreatment with
pertussis toxin significantly potentiated the oxytocin response to
8-OH-DPAT (by 206.4%; Fig. 7A). The two-way ANOVA indicated
no significant main effect of pertussis toxin
(F(1,31) = 2.94; p > 0.05), a significant main effect of 8-OH-DPAT
(F(1,31) = 22.02; p < 0.0001), and no significant interaction between pertussis toxin and
8-OH-DPAT (F(1,31)= 2.53; p > 0.1). However, a post hoc
Newman-Keuls' test indicated that the oxytocin response to 8-OH-DPAT
was significantly potentiated in rats pretreated with pertussis toxin,
when compared with rats pretreated with vehicle
(p < 0.05).

View larger version (22K):
[in this window]
[in a new window]
|
Figure 7.
Effect of pretreatment with pertussis toxin (1 µg, i.c.v.) on the oxytocin (A), ACTH
(B), and prolactin (C)
responses to 8-OH-DPAT (50 µg/kg, s.c.). The data represent the
mean ± SEM of 8-10 rats per group. *Significant effect of
pertussis toxin, p < 0.01 (Newman-Keuls'
test).
|
|
Pretreatment with pertussis toxin did not alter the basal levels of
ACTH (Fig. 7B). Administration of 8-OH-DPAT to rats that were pretreated with an intracerebroventricular injection of saline significantly elevated plasma levels of ACTH (by 1031%). The ACTH response to 8-OH-DPAT was not significantly affected by treatment with
pertussis toxin (Fig. 7B). The two-way ANOVA indicated no significant main effect of pertussis toxin
(F(1,32) = 0.95; p > 0.1), a significant main effect of 8-OH-DPAT
(F(1,32) = 39.1; p < 0.0001), and no significant interaction between pertussis toxin and
8-OH-DPAT (F(1,32) = 1.27;
p > 0.1).
In contrast with its effects on ACTH and oxytocin, pertussis toxin
treatment significantly reduced the basal plasma levels of prolactin
(to 38.2% of control; Fig. 7C). 8-OH-DPAT also
significantly increased the plasma levels of prolactin in rats that
were pretreated with vehicle (by 162%; Fig. 7C).
Pretreatment with pertussis toxin significantly blocked the
8-OH-DPAT-induced elevation of plasma prolactin (Fig. 7C).
The two-way ANOVA indicated a significant main effect of pertussis
toxin (F(1,30) = 22.82;
p < 0.0001), a significant main effect of 8-OH-DPAT
(F(1,30) = 6.75; p < 0.05), but no significant interaction between pertussis toxin and
8-OH-DPAT (F(1,30) = 1.23;
p > 0.1). The post hoc Newman-Keuls' test
indicated that the prolactin response to 8-OH-DPAT was significantly
inhibited in rats pretreated with pertussis toxin when compared with
rats pretreated with vehicle (p < 0.01).
 |
DISCUSSION |
This study provides functional in vivo evidence for the
coupling of Gz-proteins to
5-HT1A receptors in the hypothalamic
paraventricular nucleus. We have established that
Gz mRNA and Gz-protein are
expressed in the hypothalamic paraventricular nucleus and that an
antisense oligodeoxynucleotide-induced reduction in the levels of
Gz-protein inhibits the ACTH and oxytocin
responses to a 5-HT1A agonist. These observations
suggest that Gz-proteins transduce signals from
5-HT1A receptors to the secretion of ACTH and oxytocin.
Cotransfection experiments in cell lines indicate that
Gz-proteins can couple to a variety of receptors
such as µ- and -opioid, 2-adrenergic,
dopamine-D2, adenosine-A1,
and 5-HT1A receptors (Ho and Wong, 1998 ).
However, because Gz-protein is expressed in large
quantities in these cell lines, coupling of
Gz-protein to a receptor subtype might not be of
physiological significance. Such studies have to be validated by
in vivo approaches.
8-OH-DPAT is the prototypical 5-HT1A agonist used
in neuroendocrine research. It has a high affinity for
5-HT1A receptors and a 10- to 100-fold lower
affinity for other 5-HT receptor subtypes (Hoyer et al., 1994 ; Jasper
et al., 1997 ). The dose of 8-OH-DPAT was selected to be submaximal and
close to its ED50 value to minimize activation of
other receptors (Li et al., 1993 ). Activation of 5-HT1A receptors stimulates the secretion of
oxytocin and CRH (Pan and Gilbert, 1992 ; Bagdy, 1998 ). Increased
release of CRH stimulates the secretion of ACTH from the pituitary
gland (Bagdy, 1998 ). The 8-OH-DPAT-induced elevation in plasma ACTH and
oxytocin levels is inhibited by the selective
5-HT1A antagonist WAY-100,635 (Vicentic et al.,
1998 ). In contrast, the prolactin response to 8-OH-DPAT is not
antagonized by WAY-100,635, indicating that it is not mediated by
5-HT1A receptors (Vicentic et al., 1998 ).
Therefore, prolactin measurements provided a control for the
selectivity of effects on 5-HT1A receptor signaling.
Antisense oligodeoxynucleotides are readily degraded (Morris and Li,
1998 ). To increase their cellular stability, we used phosphorothioate-modified oligodeoxynucleotides. Our initial
experiment, using oligodeoxynucleotides in which all bases were
phosphorothioate modified, resulted in a reduction in the levels
of Gz and a 40-50% inhibition of the oxytocin and ACTH responses
to 8-OH-DPAT, compared with the missense and uninjected control
groups. However, this sequence of phosphorothioate-modified
Gz antisense oligodeoxynucleotides produced a
reduction in both Gi1- and
Gi2-protein levels. The nonspecific effect of
this antisense oligodeoxynucleotide is likely attributable to its
sequence, because the phosphorothioate-modified missense
oligodeoxynucleotide did not reduce the levels of
Gi1- or Gi2-proteins.
Therefore, in a subsequent experiment, we changed the sequence of the
oligodeoxynucleotides, and only the two bases at each end were
phosphorothioate-modified. These longer and less modified
oligodeoxynucleotides were more selective for
Gz-protein because the levels of
Gi1- and Gi2-proteins in
the paraventricular nucleus were not reduced. Furthermore, the baseline
levels of hormones were not different in missense- or antisense
oligodeoxynucleotide-treated groups, compared with uninjected controls.
Thus, both Gz antisense oligodeoxynucleotides
have a common effect on the levels of Gz-proteins and on the ACTH and oxytocin response to the
5-HT1A agonist. The lack of significant reduction
in Gz-protein level, in missense-treated rats,
was further confirmed by the lack of a significant inhibition of the
hormone responses to 8-OH-DPAT, compared with the uninjected controls.
The decrease in Gz-protein levels, after
antisense treatment, induced a proportional inhibition of the oxytocin
and ACTH responses to 8-OH-DPAT. Oxytocin synthesizing cells are
located in the paraventricular nucleus and release oxytocin directly
into the bloodstream from the neurohypophysis. Therefore, changes in
plasma levels of oxytocin provide a direct and sensitive indicator of
changes in Gz-protein-coupled 5-HT1A receptor function in the hypothalamus.
The data obtained using both antisense oligodeoxynucleotides and
pertussis toxin suggest that pertussis toxin-sensitive
Gi/o-proteins do not mediate
5-HT1A receptor-induced ACTH secretion and that ACTH secretion is under the control of the pertussis toxin-insensitive Gz-protein. ACTH secretion is amplified because
it is mediated by activation of CRH receptors, which are coupled via
G-proteins to effector enzymes. Therefore, any decrease in
5-HT1A receptor signaling could be masked by the
amplification by CRH of ACTH release. Consequently, the observed
decrease in ACTH would not be expected to reflect a proportional
decrease in 5-HT1A receptor systems in the
paraventricular nucleus. The fact that Gz
antisense oligodeoxynucleotide treatment produced an ~40% decrease
of the ACTH response to 8-OH-DPAT suggests a possibility of a much
larger decrease of 5-HT1A receptor function in
CRH cells.
Pertussis toxin-sensitive G-proteins include members of the
Gi-protein family such as
Gi1-, Gi2-,
Gi3-, and Go-proteins (Hamm and Gilchrist, 1996 ; Fields and Casey, 1997 ). Proteins insensitive to
pertussis toxin include Gq/11-,
Gs-, and Gz-proteins
(Fields and Casey, 1997 ). 5-HT1A receptors have a
very low affinity for Gs and
Gq/11-proteins (Butkerait et al., 1995 ; Albert et
al., 1996 ), and it is not likely that these G-proteins mediate the effect of 5-HT1A receptors on the secretion of
ACTH and oxytocin. To our knowledge, all in vivo evidence
reported to date suggests that, in other brain regions such as the
dorsal raphe and hippocampus, the physiological effects of
5-HT1A receptor activation are mediated by
pertussis toxin-sensitive Gi/o-proteins (Clarke
et al., 1987 ; Innis and Aghajanian, 1987 ; Blier et al., 1993 ; Romero et
al., 1994 ).
In the present study, we used a relatively low dose (1 µg, i.c.v.) of
pertussis toxin to prevent its toxic side effects. However, this
pertussis toxin dose (1 µg, i.c.v.) is equal to or higher than doses
that were previously shown to affect physiological responses to
activation of other receptors that are coupled to Gi- and/or Go-proteins,
such as µ-opioid receptors (Parolaro et al., 1990 ; Lin and Pan,
1996 ), dopamine-D2 receptors (Okada et al.,
1994 ), and substance P receptors (Bot and Chahl, 1993 ). The failure of
pertussis toxin to inhibit the ACTH and oxytocin responses to
8-OH-DPAT, combined with the inhibition of the ACTH and oxytocin responses to 8-OH-DPAT by Gz antisense
oligodeoxynucleotides, suggests that Gz-proteins
are the key component in 5-HT1A receptor signaling in the hypothalamic paraventricular nucleus.
An unexpected finding was the oxytocin response to 8-OH-DPAT, which was
potentiated instead of reduced by pertussis toxin. One explanation for
this potentiated response is that other receptors that are coupled to
Gi- and/or Go-proteins
inhibit the secretion of oxytocin. For example, µ-opioid receptors
inhibit the secretion of oxytocin (Pumford et al., 1993 ; Ingram et al.,
1996 ). Similar to our results, the opioid antagonist naloxone
potentiated the oxytocin response to another stimulus (systemic
injection of cholecystokinin) without altering basal oxytocin levels
(Leng et al., 1992 ). Another possible explanation is that hypothalamic
Gi/o-proteins compete with
Gz-proteins for 5-HT1A
receptor coupling, but only Gz-proteins would
mediate the effects on oxytocin secretion. Inactivation of
Gi/o-proteins by pertussis toxin would thus allow
an increased coupling efficiency of Gz-protein to
5-HT1A receptors, resulting in an enhanced
secretion to the same 8-OH-DPAT dose.
We measured plasma prolactin levels as a control measure on the
specificity and effectiveness of our treatments. As mentioned earlier,
the effect of 8-OH-DPAT on the secretion of prolactin is not
exclusively mediated by 5-HT1A receptors and
involves other, as yet uncharacterized, mechanisms (Aulakh et al.,
1988 ; Vicentic et al., 1998 ). The injection of Gz
antisense oligodeoxynucleotides did not inhibit the prolactin response
to 8-OH-DPAT, supporting our conclusion that
Gz-proteins specifically couple
5-HT1A receptors to the stimulation of oxytocin
and ACTH secretion.
The pertussis toxin-induced inhibition of basal as well as
8-OH-DPAT-induced increase of prolactin release could be explained as a
consequence of increased activity of tuberoinfundibular dopamine neurons. For example, receptors that are coupled to pertussis toxin-sensitive Gi-proteins, such as µ-opioid
receptors (Parolaro et al., 1990 ; Chan et al., 1995 ), mediate a tonic
inhibition of the activity of tuberoinfundibular dopamine neurons in
the hypothalamus (Callahan et al., 1996 ). Therefore, pertussis
toxin-induced inactivation of Gi/o-proteins
coupled to the µ-opioid receptors in the hypothalamus could produce a
disinhibition of dopaminergic neurons and result in increased release
of dopamine. Increased dopamine levels in the anterior pituitary gland
inhibit the secretion of prolactin, regardless of the presence of other
stimuli that increase its secretion (Pilotte and Porter, 1981 ; Callahan
et al., 1996 ). This explanation is consistent with the observation that
pertussis toxin treatment reduced basal prolactin levels.
In conclusion, the present study provides the first in vivo
evidence demonstrating that Gz-proteins couple
5-HT1A receptors in the hypothalamus to effector
systems that trigger the secretion of ACTH and oxytocin. These data
suggest that the ACTH and oxytocin responses to
5-HT1A agonists can be used as peripheral markers of alterations in hypothalamic 5-HT1A receptors
signal transduction via altered coupling of
Gz-protein.
 |
FOOTNOTES |
Received Jan. 21, 2000; revised Feb. 10, 2000; accepted Feb. 17, 2000.
This work was supported in part by United States Public Health Service
Grants NS34153 and MH58448 (L.D.V.), Loyola Neuroscience and Aging
Institute (F.S.), and National Alliance for Research on Schizophrenia
and Depression (D.K.R.).
Correspondence should be addressed to Dr. Louis D. Van de Kar,
Department of Pharmacology, Stritch School of Medicine, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153. E-mail:
lvandek{at}luc.edu.
Dr. Serres' present address: Lilly Research Center, Erl Wood Manor,
Sunninghill Road, Windlesham Surrey GU20 6PH, UK.
Dr. Raap's present address: Department of Psychology, University of
Alaska Fairbanks, Fairbanks, Alaska 99775.
 |
REFERENCES |
-
Albert PR,
Lembo P,
Storring JM,
Charest A,
Saucier C
(1996)
The 5HT1A receptor: signaling, desensitization, and gene transcription.
Neuropsychopharmacology
14:19-25[Web of Science][Medline].
-
Aulakh CS,
Wozniak KM,
Haas M,
Hill JL,
Zohar J,
Murphy DL
(1988)
Food intake, neuroendocrine and temperature effects of 8-OHDPAT in the rat.
Eur J Pharmacol
146:253-259[Web of Science][Medline].
-
Bagdy G
(1996)
Role of the hypothalamic paraventricular nucleus in 5-HT1A, 5-HT2A and 5-HT2C receptor-mediated oxytocin, prolactin and ACTH/corticosterone responses.
Behav Brain Res
73:277-280[Web of Science][Medline].
-
Bagdy G
(1998)
The role of biogenic amines in neuroendocrine regulation in conscious rats.
In: Methods in neuroendocrinology (Van de Kar LD,
ed), pp 145-161. Boca Raton: CRC.
-
Barr AJ,
Brass LF,
Manning DR
(1997)
Reconstitution of receptors and GTP-binding regulatory proteins (G proteins) in Sf9 cells. A direct evaluation of selectivity in receptor G protein coupling.
J Biol Chem
272:2223-2229[Abstract/Free Full Text].
-
Blier P,
Lista A,
de Montigny C
(1993)
Differential properties of pre- and postsynaptic 5-hydroxytryptamine1A receptors in the dorsal raphe and hippocampus: I. Effect of spiperone.
J Pharmacol Exp Ther
265:7-15[Abstract/Free Full Text].
-
Bot G,
Chahl LA
(1993)
Effects of pertussis toxin on behavioural responses of guinea-pigs to centrally administered substance P, quinpirol, carbachol, U-50,488H, morphine and morphine withdrawal.
Eur J Pharmacol
231:53-60[Medline].
-
Butkerait P,
Zheng Y,
Hallak H,
Graham TE,
Miller HA,
Burris KD,
Molinoff PB,
Manning DR
(1995)
Expression of the human 5-hydroxytryptamine1A receptor in Sf9 cells. Reconstitution of a coupled phenotype by co-expression of mammalian G protein subunits.
J Biol Chem
270:18691-18699[Abstract/Free Full Text].
-
Callahan P,
Baumann MH,
Rabii J
(1996)
Inhibition of tuberoinfundibular dopaminergic neural activity during suckling: involvement of mu and kappa opiate receptor subtypes.
J Neuroendocrinol
8:771-776[Web of Science][Medline].
-
Calogero AE,
Bernardini R,
Margioris AN,
Bagdy G,
Gallucci WT,
Tamarkin L,
Tomai TP
(1989)
Effect of serotonergic agonists and antagonists on corticotropin-releasing hormone secretion by explanted rat hypothalami.
Peptides
10:189-200[Web of Science][Medline].
-
Casey PJ,
Fong HK,
Simon MI,
Gilman AG
(1990)
Gz, a guanine nucleotide-binding protein with unique biochemical properties.
J Biol Chem
265:2383-2390[Abstract/Free Full Text].
-
Chan JS,
Chiu TT,
Wong YH
(1995)
Activation of type II adenylyl cyclase by the cloned mu-opioid receptor: coupling to multiple G proteins.
J Neurochem
65:2682-2689[Web of Science][Medline].
-
Clarke WP,
De Vivo M,
Beck SG,
Maayani S,
Goldfarb J
(1987)
Serotonin decreases population spike amplitude in hippocampal cells through a pertussis toxin substrate.
Brain Res
410:357-361[Web of Science][Medline].
-
Cowen PJ
(1998)
Neuroendocrine challenge tests: what can we learn from them?
In: Methods in neuroendocrinology (Van de Kar LD,
ed), pp 205-223. Boca Raton: CRC.
-
Fields TA,
Casey PJ
(1997)
Signaling functions and biochemical properties of pertussis toxin-resistant G-proteins.
Biochem J
321:561-571.
-
Fong HK,
Yoshimoto KK,
Eversole-Cire P,
Simon MI
(1988)
Identification of a GTP-binding protein alpha subunit that lacks an apparent ADP-ribosylation site for pertussis toxin.
Proc Natl Acad Sci USA
85:3066-3070[Abstract/Free Full Text].
-
Hamm HE,
Gilchrist A
(1996)
Heterotrimeric G proteins.
Curr Opin Cell Biol
8:189-196[Web of Science][Medline].
-
Ho MKC,
Wong YH
(1998)
Structure and function of the pertussis-toxin-insensitive Gz protein.
Biol Signals
7:80-89.
-
Hoyer D,
Clarke DE,
Fozard JR,
Hartig PR,
Martin GR,
Mylecharane EJ,
Saxena PR,
Humphrey PPA
(1994)
VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin).
Pharmacol Rev
46:157-204[Abstract].
-
Ingram CD,
Kavadas V,
Thomas MRM,
Threapleton JD
(1996)
Endogenous opioid control of somatodendritic oxytocin release from the hypothalamic supraoptic and paraventricular nuclei in vitro.
Neurosci Res
25:17-24[Medline].
-
Innis RB,
Aghajanian GK
(1987)
Pertussis toxin blocks 5-HT1A and GABAB receptor-mediated inhibition of serotonergic neurons.
Eur J Pharmacol
143:195-204[Web of Science][Medline].
-
Jasper JR,
Kosaka A,
To ZP,
Chang DJ,
Eglen RM
(1997)
Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7(b)).
Br J Pharmacol
122:126-132[Web of Science][Medline].
-
Kawano S,
Osaka T,
Kannan H,
Yamashita H
(1992)
Excitation of hypothalamic paraventricular neurons by stimulation of the raphe nuclei.
Brain Res Bull
28:573-579[Web of Science][Medline].
-
Leng G,
Dyball REJ,
Way SA
(1992)
Naloxone potentiates the release of oxytocin induced by systemic administration of cholecystokinin without enhancing the electrical activity of supraoptic oxytocin neurones.
Exp Brain Res
88:321-325[Medline].
-
Li Q,
Levy AD,
Cabrera TM,
Brownfield MS,
Battaglia G,
Van de Kar LD
(1993)
Long-term fluoxetine, but not desipramine, inhibits the ACTH and oxytocin responses to the 5-HT1A agonist 8-OH-DPAT in male rats.
Brain Res
630:148-156[Web of Science][Medline].
-
Li Q,
Battaglia G,
Van de Kar LD
(1997a)
Autoradiographic evidence for differential G-protein coupling of 5-HT1A receptors in the rat brain: lack of effect by repeated injections of fluoxetine.
Brain Res
769:141-151[Web of Science][Medline].
-
Li Q,
Muma NA,
Battaglia G,
Van de Kar LD
(1997b)
A desensitization of hypothalamic 5-HT1A receptors by repeated injections of paroxetine: reduction in the levels of Gi and Go proteins and neuroendocrine responses, but not in the density of 5-HT1A receptors.
J Pharmacol Exp Ther
282:1581-1590[Abstract/Free Full Text].
-
Lin JY,
Pan JT
(1996)
Prolonged pertussis toxin treatment affects morphine's action on tuberoinfundibular dopaminergic neuron activity and on prolactin secretion.
Brain Res
727:182-186[Medline].
-
Liposits Z,
Phelix C,
Paull WK
(1987)
Synaptic interaction of serotonergic axons and corticotropin releasing factor (CRF) synthesizing neurons in the hypothalamic paraventricular nucleus of the rat. A light and electron microscopic immunocytochemical study.
Histochemistry
86:541-549[Web of Science][Medline].
-
Lowry OH,
Rosebrough WY,
Farr AL,
Randall RJ
(1951)
Protein measurement with the folin phenol reagent.
J Biol Chem
193:265-275[Free Full Text].
-
Matsuoka M,
Itoh H,
Kozasa T,
Kaziro Y
(1988)
Sequence analysis of cDNA and genomic DNA for a putative pertussis toxin-insensitive guanine nucleotide-binding regulatory protein alpha subunit.
Proc Natl Acad Sci USA
85:5384-5388[Abstract/Free Full Text].
-
Morris M,
Li P
(1998)
Antisense oligonucleotides as tools in neuroendocrinology.
In: Methods in neuroendocrinology (Van de Kar LD,
ed), pp 131-144. Boca Raton: CRC.
-
Mullaney I,
Miligan G
(1990)
Identification of two distinct isoforms of the guanine nucleotide binding protein Go in neuroblastoma X glioma hybrid cells: independent regulation during cyclic AMP-induced differentiation.
J Neurochem
55:1890-1898[Web of Science][Medline].
-
Muma NA,
Hoffman PN,
Slunt HH,
Applegate MD,
Lieberburg I,
Price DL
(1990)
Alterations in levels of mRNAs coding for neurofilament protein subunits during regeneration.
Exp Neurol
107:230-235[Web of Science][Medline].
-
Okada F,
Takahashi N,
Ito A,
Tokumitsu Y,
Nomura Y
(1994)
Acceleration of desipramine-induced changes on the dopamine receptor-coupled adenylate cyclase system by pertussis toxin.
J Neural Transm
98:133-142[Medline].
-
Pan L,
Gilbert F
(1992)
Activation of 5-HT1A receptor subtype in the paraventricular nuclei of the hypothalamus induces CRH ACTH release in the rat.
Neuroendocrinology
56:797-802[Web of Science][Medline].
-
Parolaro D,
Patrini G,
Giagnoni G,
Massi P,
Groppetti A,
Parenti M
(1990)
Pertussis toxin inhibits morphine analgesia and prevents opiate dependence.
Pharmacol Biochem Behav
35:137-141[Medline].
-
Paxinos G,
Watson C
(1986)
In: The rat brain in stereotaxic coordinates. Sydney: Academic.
-
Pilotte NS,
Porter JC
(1981)
Dopamine in hypophysial portal plasma and prolactin in systemic plasma of rats treated with 5-hydroxytryptamine.
Endocrinology
108:2137-2141[Abstract/Free Full Text].
-
Pumford KM,
Leng G,
Russell JA
(1993)
A pertussis toxin-sensitive G protein mediates inhibition by morphine of spontaneous electrical activity of oxytocin neurons in anaesthetized rats.
Exp Brain Res
94:247-251[Medline].
-
Romero L,
Celada P,
Artigas F
(1994)
Reduction of in vivo striatal 5-hydroxytryptamine release by 8-OH-DPAT after inactivation of Gi/Go proteins in dorsal raphe nucleus.
Eur J Pharmacol
265:103-106[Web of Science][Medline].
-
Sanchez-Blazquez P,
Garcia-Espana A,
Garzon J
(1995)
In vivo injection of antisense oligodeoxynucleotides to G alpha subunits and supraspinal analgesia evoked by mu and delta opioid agonists.
J Pharmacol Exp Ther
275:1590-1596[Abstract/Free Full Text].
-
Saphier D
(1991)
Paraventricular nucleus magnocellular neuronal responses following electrical stimulation of the midbrain dorsal raphe.
Exp Brain Res
85:359-363[Medline].
-
Steel RGD,
Torrie JH
(1960)
In: Principles and procedures of statistics with special reference to the biological sciences. New York: McGraw-Hill.
-
Vicentic A,
Li Q,
Battaglia G,
Van de Kar LD
(1998)
WAY-100635 inhibits 8-OH-DPAT stimulated oxytocin, ACTH, and corticosterone, but not prolactin secretion.
Eur J Pharmacol
346:261-266[Web of Science][Medline].
Copyright © 2000 Society for Neuroscience 0270-6474/00/2093095-09$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
C. M. la Cour, S. El Mestikawy, N. Hanoun, M. Hamon, and L. Lanfumey
Regional Differences in the Coupling of 5-Hydroxytryptamine-1A Receptors to G Proteins in the Rat Brain
Mol. Pharmacol.,
September 1, 2006;
70(3):
1013 - 1021.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Andric, D. Zivadinovic, A. E. Gonzalez-Iglesias, A. Lachowicz, M. Tomic, and S. S. Stojilkovic
Endothelin-induced, Long Lasting, and Ca2+ Influx-independent Blockade of Intrinsic Secretion in Pituitary Cells by Gz Subunits
J. Biol. Chem.,
July 22, 2005;
280(29):
26896 - 26903.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. J. Damjanoska, B. A. Heidenreich, G. H. Kindel, D. N. D'Souza, Y. Zhang, F. Garcia, G. Battaglia, W. A. Wolf, L. D. Van de Kar, and N. A. Muma
Agonist-Induced Serotonin 2A Receptor Desensitization in the Rat Frontal Cortex and Hypothalamus
J. Pharmacol. Exp. Ther.,
June 1, 2004;
309(3):
1043 - 1050.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. N. D'Souza, Y. Zhang, F. Garcia, G. Battaglia, and L. D. Van de Kar
Fluoxetine-induced changes in body weight and 5-HT1A receptor-mediated hormone secretion in rats on a tryptophan-deficient diet
Am J Physiol Regulatory Integrative Comp Physiol,
February 1, 2004;
286(2):
R390 - R397.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Tu, S. K. Nayak, J. Woodson, and E. M. Ross
Phosphorylation-regulated Inhibition of the Gz GTPase-activating Protein Activity of RGS Proteins by Synapsin I
J. Biol. Chem.,
December 26, 2003;
278(52):
52273 - 52281.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. A. Carrasco, Y. Zhang, K. J. Damjanoska, D. N. D'Souza, F. Garcia, G. Battaglia, N. A. Muma, and L. D. Van de Kar
A Region-Specific Increase in G{alpha}q And G{alpha}11 Proteins in Brains of Rats during Cocaine Withdrawal
J. Pharmacol. Exp. Ther.,
December 1, 2003;
307(3):
1012 - 1019.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhang, D. D'Souza, D. K. Raap, F. Garcia, G. Battaglia, N. A. Muma, and L. D. Van de Kar
Characterization of the Functional Heterologous Desensitization of Hypothalamic 5-HT1A Receptors after 5-HT2A Receptor Activation
J. Neurosci.,
October 15, 2001;
21(20):
7919 - 7927.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. L. J. Evans, J. D. Cropper, K. A. Berg, and W. P. Clarke
Mechanisms of Regulation of Agonist Efficacy at the 5-HT1A Receptor by Phospholipid-Derived Signaling Components
J. Pharmacol. Exp. Ther.,
June 1, 2001;
297(3):
1025 - 1035.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
Q. Li, C. Wichems, A. Heils, K.-P. Lesch, and D. L. Murphy
Reduction in the Density and Expression, But Not G-Protein Coupling, of Serotonin Receptors (5-HT1A) in 5-HT Transporter Knock-Out Mice: Gender and Brain Region Differences
J. Neurosci.,
November 1, 2000;
20(21):
7888 - 7895.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Serres, N. A. Muma, D. K. Raap, F. Garcia, G. Battaglia, and L. D. Van de Kar
Coadministration of 5-Hydroxytryptamine1A Antagonist WAY-100635 Prevents Fluoxetine-Induced Desensitization of Postsynaptic 5-Hydroxytryptamine1A Receptors in Hypothalamus
J. Pharmacol. Exp. Ther.,
July 1, 2000;
294(1):
296 - 301.
[Abstract]
[Full Text]
|
 |
|
|